What Factors Should I Consider Before Deciding Whether to Get a Prostate Biopsy?

A physician’s perspective on what PSA trends, imaging, symptoms, age, overall health, and personal risk reveal before deciding whether to undergo a prostate biopsy.

By Stephen Petteruti, DO

Board-Certified Family Physician | Founder, Intellectual Medicine | Last reviewed July 2026

Being told you need a prostate biopsy can feel overwhelming. For many men, the recommendation comes quickly after a rising PSA, abnormal MRI, or concerning screening result. The conversation often moves fast, and patients are often left feeling pressured to make a major decision before fully understanding what a biopsy involves or whether it is truly necessary.

One of the biggest mistakes men make is assuming a biopsy is automatically the next step. In reality, this decision deserves careful thought. A prostate biopsy is an invasive procedure with real risks, limitations, and long-term consequences that should be fully understood before moving forward.

Understanding the Purpose of a Prostate Biopsy

A prostate biopsy is designed to collect tissue samples from the prostate to look for cancer cells. Traditionally, it has been considered the standard method for diagnosing prostate cancer and determining how aggressive the disease may appear.

While a biopsy can provide useful information, it is still only one piece of the puzzle. Like any invasive procedure, it comes with tradeoffs. Before agreeing to a biopsy, patients should understand not only what information it may provide, but also what risks and limitations come with it.

PSA Levels and Trends Matter More Than a Single Number

One of the most common reasons men are referred for biopsy is an elevated PSA. The problem is that many men are pushed toward invasive testing based on one lab result, even though a single PSA value rarely tells the full story.

PSA levels can rise for many reasons outside of cancer, including prostate enlargement, inflammation, infection, recent ejaculation, exercise, and simple lab variability. A high PSA does not automatically mean cancer. In fact, research has consistently shown PSA testing has limitations in specificity, meaning many men with elevated PSA do not have clinically significant prostate cancer.

What often matters far more is the trend over time. Has PSA remained stable? Is it gradually rising? Was there a sudden spike? Has the number been interpreted in the context of age and prostate size? These are the kinds of questions that often provide more useful insight than one isolated result.

MRI Findings Should Be Part of the Decision

MRI has become one of the most useful tools in prostate evaluation because it provides valuable information without immediately moving to invasive testing. A high-quality prostate MRI can help identify suspicious areas, estimate lesion risk, and offer greater clarity about what may be happening.

Research has strengthened the role of MRI in prostate evaluation. Studies such as the PROMIS trial have shown that multiparametric MRI can improve detection of clinically significant prostate cancer while helping reduce unnecessary biopsies in some men. MRI findings should always be interpreted alongside PSA trends and the broader clinical picture. Not every abnormal MRI means aggressive cancer, and not every concerning PSA result requires immediate biopsy. The goal is to gather better information before making major decisions.

Understanding the Risks of Prostate Biopsy

Many men are never fully informed about the risks associated with biopsy. Infection, bleeding, pain, urinary complications, and temporary discomfort are all possible. Published studies have shown that prostate biopsy complications are not insignificant, with infection and hospitalization remaining important considerations, particularly with repeated procedures.

One of the biggest concerns is sampling error. A biopsy only samples small pieces of the prostate, which means it can miss areas of concern or fail to accurately represent the full picture. This creates the possibility of both false reassurance and unnecessary anxiety.

Biopsy can also lead to overdiagnosis and overtreatment. Large screening studies have shown that many prostate cancers identified through aggressive screening are slow growing and may never become life-threatening. Yet once the word cancer enters the conversation, many men feel immediate pressure to pursue surgery or radiation.

Consider How the Results Will Change Your Decision-Making

An important questions to ask before agreeing to a biopsy: how will the result actually change your decisions?

Would the findings immediately change your treatment plan? Would you automatically pursue surgery or radiation if cancer were found? Or would the results simply create more uncertainty without changing how you plan to monitor the situation?

Testing should help guide meaningful decisions. It should create clarity, not simply generate more fear.

Are There Alternatives to Immediate Biopsy?

For some men, additional monitoring or non-invasive evaluation may be a reasonable next step before committing to biopsy. This may include repeating PSA testing, obtaining advanced blood work, reviewing PSA density, or using MRI to gather more information.

In many cases, better decisions are made by first improving the quality of the data. The goal should not be rushing toward intervention. The goal should be gaining clarity before taking action.

Making an Informed Decision

There is no single answer that fits every patient, but I believe every man deserves to fully understand what a biopsy does and does not accomplish before making that decision.

A biopsy may provide additional diagnostic information, and for some men, that information can offer greater clarity or peace of mind. But more information does not always lead to better outcomes, especially when that information creates fear, uncertainty, or pressure to pursue aggressive treatment that may not improve longevity.

The most important part of this process is making decisions based on good data, thoughtful analysis, and a clear understanding of both risks and limitations. Fear should never drive medical decision-making. The goal should always be gaining enough clarity to make smart, informed decisions that protect both longevity and quality of life.

Final Thoughts

Deciding whether to get a prostate biopsy is a significant decision, and it deserves careful consideration. Before moving forward, make sure you understand why the biopsy is being recommended, what information it is expected to provide, what the risks are, and how the results would actually influence your next steps.

Too many men are rushed into invasive testing without fully understanding the downstream consequences. Fear should never drive decisions this important.

Before agreeing to a biopsy, I encourage you to watch my podcasts, Think Twice Before a Prostate Biopsy: The Evidence You Need to Hear and Don’t Biopsy Your Prostate Until You Hear This (Part 2). These conversations break down the evidence, the risks, and the questions every man should be asking before moving forward.

If you want personalized guidance on elevated PSA, MRI findings, or prostate cancer decision-making, schedule a consultation with Intellectual Medicine. My goal is to help you make clear, informed decisions that protect both longevity and quality of life.

About Dr. Stephen Petteruti

Stephen Petteruti, DO, is a board-certified family physician specializing in men’s health, hormone optimization, longevity, and prostate cancer care. His approach focuses on root causes, metabolic health, informed decision-making, and long-term vitality. His goal is to help patients protect their strength, energy, independence, and quality of life as they age. 

Dr. Petteruti is the best-selling author of Fight Cancer Like a Man, available in hardcover, paperback, Kindle, and audiobook formats. He also hosts the Intellectual Medicine Podcast, where he discusses prostate cancer, testosterone, longevity, medical testing, and the treatment decisions patients often face.

Learn more about Dr. Petteruti, read Fight Cancer Like a Man, and listen to the Intellectual Medicine Podcast. You can also visit his personal website here. 

References

1. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. doi:10.1016/S0140-6736(16)32401-1
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 1.2025. NCCN; 2025.
3. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419-426. doi:10.1016/j.juro.2013.04.119
4. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830-1834. doi:10.1016/j.juro.2011.06.057
5. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-2035. doi:10.1016/S0140-6736(14)60525-0